Hypothesis

Loss of membrane α‑Klotho creates a local phosphate excess that activates the Wnt/β‑catenin pathway, which transcriptionally upregulates the NAD‑consuming enzyme CD38 in kidney tubules and downstream tissues. The resulting surge in CD38 activity hydrolyzes NAD+, lowering cellular NAD+ pools independent of NAMPT‑mediated biosynthesis. Thus NAD+ decline is a downstream consequence of Klotho‑FGF23‑driven mineral dysregulation rather than a primary driver of aging.

Rationale

• Membrane Klotho is obligate co‑receptor for FGF23 in proximal tubules, controlling phosphate excretion [1]. Klotho loss yields FGF23 resistance and compensatory FGF23 overproduction, raising circulating phosphate [2].
• Soluble Klotho (sKlotho) inhibits Wnt/β‑catenin signaling; its depletion lifts this brake, allowing β‑catenin‑dependent transcription [3].
• Wnt/β‑catenin activation has been shown to increase CD38 promoter activity in immune cells (though not yet demonstrated in renal epithelium) [7].
• CD38 is a major NADase whose activity rises with age and correlates with NAD+ depletion [6].
• No study has directly linked Klotho/FGF23 signaling to NAMPT, sirtuins, or CD38 expression, positioning NAD+ loss as a plausible secondary effect.

Novel Mechanistic Insight

We propose that intracellular phosphate acts as a signaling molecule that stabilizes β‑catenin by inhibiting GSK3β activity, similar to how high glucose stabilizes HIF‑1α. In Klotho‑deficient cells, excess phosphate reduces GSK3β‑mediated β‑catenin phosphorylation, leading to nuclear accumulation and transcription of CD38. This creates a feed‑forward loop: CD38‑mediated NAD+ loss impairs SIRT1 deacetylase activity, further reducing Klotho expression via increased p16INK4a activity [5], amplifying the deficit.

Testable Predictions

1. In Klotho‑knockout mice, renal tubular CD38 mRNA and protein will be elevated proportionally to serum phosphate levels.
2. Pharmacological reduction of dietary phosphate will normalize CD38 expression and restore NAD+ despite persistent Klotho deficiency.
3. Specific inhibition of CD38 (e.g., with 78c) will rescue NAD+ levels and ameliorate mitochondrial dysfunction in Klotho‑deficient progenitor cells without altering NAMPT expression.
4. Activating Wnt/β‑catenin (via CHIR99021) in wild‑type tubules will recapitulate CD38 upregulation and NAD+ loss, whereas β‑catenin siRNA will block the effect in Klotho‑deficient cells.

Experimental Design

• Animal cohorts: WT, Klotho‑KO, and Klotho‑KO fed low‑phosphate diet (0.2% vs 1.2% phosphate) for 12 weeks. Measure serum phosphate, FGF23, renal CD38 (qPCR, immunoblot), NAD+ (LC‑MS), and SIRT1 activity.
• Intervention arms: Subsets receive CD38 inhibitor 78c (10 mg/kg i.p. twice weekly) or vehicle.
• Cellular model: Human proximal tubular (HK‑2) cells transfected with siRNA against Klotho or treated with soluble Klotho‑Fc. Manipulate phosphate concentration (5 mM vs 20 mM) and assess β‑catenin nuclear localization (immunofluorescence), CD38 transcription (luciferase reporter), and NAD+ levels.
• Readouts: Mitochondrial respiration (Seahorse), p16INK4a expression, and inflammatory markers (IL‑6, TNFα).

Potential Outcomes

• If CD38 elevation is phosphate‑ and Wnt/β‑catenin dependent, low‑phosphate diet or CD38 blockade will normalize NAD+ despite Klotho loss, falsifying the notion that NAD+ decline is irreversible without Klotho restoration.
• If NAD+ remains low despite these manipulations, the hypothesis would be weakened, suggesting alternative Klotho‑dependent pathways (e.g., direct regulation of NAMPT) dominate.

Implications

Positioning NAD+ loss as a metabolic downgrade downstream of mineral‑inflammatory signaling reframes interventions: targeting phosphate excretion, Wnt/β‑catenin, or CD38 may preserve NAD+ and organ function without requiring systemic NAD+ precursors. This aligns with the idea that the cell reduces its ‘ambition’ when homeostatic cues signal a hostile environment, conserving resources for survival rather than futile repair.

References

[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC3770142 [2] https://pmc.ncbi.nlm.nih.gov/articles/PMC11105488 [3] https://pubmed.ncbi.nlm.nih.gov/34503373 [4] https://doi.org/10.1038/s41467-018-07253-3 [5] https://doi.org/10.1038/ncomms8035 [6] https://doi.org/10.1016/j.cell.2013.11.037 [7] https://doi.org/10.1101/2024.09.08.611868